Methods of Possible Application of Cell-Free Amniotic Fluid Analogues in the Practice of a Pediatrician
https://doi.org/10.15690/pf.v22i1.2859
Abstract
The use of amniotic fluid as a source of stem cells is of great interest in cosmetology, genetics, obstetrics, neonatology and other areas of medicine. The relatively easy method of cell culture expands and reduces the cost of their use, but their indiscriminate use is fraught with the risk of developing malignant neoplasms due to the lack of control over the differentiation of multipotent cells in the patient’s body. The relatively easy method of cell culture expands and reduces the cost of their use, but their indiscriminate use is fraught with the risk of developing malignant neoplasms due to the lack of control over the differentiation of multipotent cells in the patient’s body. But even cell-free amniotic fluid is rich in a variety of cytokines that promote enterocyte protection against the effects of pro-inflammatory immune response factors and hypoxia, as well as optimal water-electrolyte composition. An analog of cell-free amniotic fluid, which includes tissue growth factors, can be a means of additional protection of the epithelium of the gastrointestinal tract, help inhibit the development of necrotic enterocolitis in reversible stages, which can reduce the number of surgical interventions in newborns and positively affect the healing of damaged epithelium at the site of intestinal wounds. The aim of this study was to find scientific evidence for this hypothesis.
Supporting agencies: Not specified.
About the Authors
Kyamal E. Gasanov
N.I. Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
student
1, Ostrovityanova Str., Moscow, 117321
Disclosure of interest:
Not declared.
Lidiya V. Sorogina
Tyumen State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
student
Tyumen
Disclosure of interest:
Not declared.
Mikhail S. Parfenov-Mamykin
N.I. Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
student
Moscow
Disclosure of interest:
Not declared.
Anna A. Tsaturova
N.I. Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
student
Moscow
Disclosure of interest:
Not declared.
References
1. S adler TW. Langman’s Medical Embryology. 14th edn. Philadelphia: Wolters Kluwer; 2019. doi: https://doi.org/10.26641/1997-9665.2019.4.90-96
2. Steed DL, Trumpower C, Duffy D, et al. Amnion-derived cellular cytokine solution: a physiological combination of cytokines for wound healing. Eplasty. 2008;8:e18.
3. Ramasamy TS, Velaithan V, Yeow Y, Sarkar FH. Stem Cells Derived from Amniotic Fluid: A Potential Pluripotent-Like Cell Source for Cellular Therapy? Curr Stem Cell Res Ther. 2018;13(4):252–264. doi: https://doi.org/10.2174/1574888X13666180115093800
4. Barkholt L, Flory E, Jekerle V, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints.Cytotherapy. 2013;15(7):753–759. doi: https://doi.org/10.1016/j.jcyt.2013.03.005
5. Mulvihill SJ, Stone MM, Fonkalsrud EW, Debas HT. Trophic effect of amniotic fluid on fetal gastrointestinal development. J Surg Res. 1986;40(4):291–296. doi: https://doi.org/10.1016/0022-4804[86]90189-7
6. Hirai C, Ichiba H, Saito M, et al. Trophic effect of multiple growth factors in amniotic fluid or human milk on cultured human fetal small intestinal cells. J Pediatr Gastroenterol Nutr. 2002;34(5):524–528.
7. Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341–348. doi: https://doi.org/10.1038/sj.jp.7211290
8. Meister AL, Doheny KK, Travagli RA. Necrotizing enterocolitis: It’s not all in the gut. Exp Biol Med (Maywood). 2020;245(2):85–95. doi: https://doi.org/10.1177/1535370219891971
9. Jones IH, Hall NJ. Contemporary Outcomes for Infants with Necrotizing Enterocolitis-A Systematic Review.J Pediatr. 2020;220:86–92.e3. doi: https://doi.org/10.1016/j.jpeds.2019.11.011
10. Hackam DJ, Sodhi CP. Toll-like receptor-mediated intestinal inflammatory imbalance in the pathogenesis of necrotizing enterocolitis. Cell Mol Gastroenterol Hepatol. 2018;6(2):229–238. e1. doi: https://doi.org/10.1016/j.jcmgh.2018.04.001
11. Egan CE, Sodhi CP, Good M, et al. Toll-like receptor 4-mediated lymphocyte influx induces neonatal necrotizing enterocolitis. J Clin Invest. 2016;126(2):495–508. doi: https://doi.org/10.1172/JCI83356
12. Good M, Siggers RH, Sodhi CP, et al. Amniotic fluid inhibits Toll-like receptor 4 signaling in the fetal and neonatal intestinal epithelium. Proc Natl Acad Sci U S A. 2012;109(28):11330–11335. doi: https://doi.org/10.1073/pnas.1200856109
13. Goldschmidt-Clermont PJ, White IA. First Case of Accelerated Healing of a Recalcitrant Diabetic Ulcer Using Purified Amniotic Fluid. Ann Case Rep. 2023;8(5):1463. doi: https://doi.org/10.29011/2574-7754.101463
14. Pierce J, Jacobson P, Benedetti E, et al. Collection and characterization of amniotic fluid from scheduled C- section deliveries. Cell Tissue Bank. 2016;17(3):413–425. doi: https://doi.org/10.1007/s10561-016-9572-7
15. Ohnishi Y, Yamashiro C, Yanagihara T, Hata T. Hepatocyte growth factor concentration in the early second-trimester amniotic fluid does not predict fetal growth at birth. Human Reproduction. 1999;14(10):2625–2628. doi: https://doi.org/10.1093/humrep/14.10.2625
16. Seikku L, Rahkonen L, Tikkanen M, et al. Amniotic fluid erythropoietin and neonatal outcome in pregnancies complicated by intrauterine growth restriction before 34 gestational weeks. Acta Obstet Gynecol Scand. 2015;94(3):288–294. doi: https://doi.org/10.1111/aogs.12553
17. Kim MH, Kim SY, Chung JH, et al. 770: Association between amniotic and cervical fluid hyaluronic acid levels at mid-trimester and spontaneous preterm delivery. Am J Obstet Gynecol. 2008;199(6). doi: https://doi.org/10.1016/j.ajog.2008.09.801
18. Pogorelova TN, Krukier II, Avrutskaya VV, Drukker NA. Molecular mechanisms of disturbance process of angiogenesis during pregnancy complicated by fetal growth retardation. Zhurnal fundamental’noi meditsiny i biologii. 2012;(1):71–75. (In Russ).]
19. Kadimova Sh. Diagnostic markers of syndrome of intrauterine growth retardation in pregnant women with renal pathology. International scientific review. 2016; 9. (In Russ).]
20. Lin XY, Wang H, Tan Y. Role of Hepatocyte Growth Factor in Wound Repair. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018;40(6):822–826. doi: https://doi.org/10.3881/j.issn.1000-503X.10246
21. York DJ, Smazal AL, Robinson DT, De Plaen IG. Human Milk Growth Factors and Their Role in NEC Prevention: A Narrative Review. Nutrients. 2021;13(11):3751. doi: https://doi.org/10.3390/nu13113751
22. Tarnawski AS, Jones MK. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol. 1998;27 Suppl 1:S12–S20. doi: https://doi.org/10.1097/00004836-199800001-00004
23. Campbell J, Wathen N, Lewis M, et al. Amniotic fluid erythropoietin levels in normal and Down’s syndrome pregnancies. Eur J Obstet Gynecol Reprod Biol. 1994;56(3):191–194. doi: https://doi.org/10.1016/0028-2243[94]90169-4
24. El-Ganzoury MM, Awad HA, El-Farrash RA, et al. Enteral granulocyte-colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. J Pediatr. 2014;165(6):1140–1145.e1. doi: https://doi.org/10.1016/j.jpeds.2014.07.034
25. Lee YS, Javan H, Reems JA, et al. Acellular human amniotic fluid protects the ischemic-reperfused rat myocardium. Am J Physiol Heart Circ Physiol. 2022;322(3):H406–H416. doi: https://doi.org/10.1152/ajpheart.00331.2021 Electrical instability of the myocardium (EIM) is a change in the electrophysiological properties of the myocardium, associated with
26. Hu X, Zhang R, Liang H, et al. Comparison and Investigation of Exosomes from Human Amniotic Fluid Stem Cells and Human Breast Milk in Alleviating Neonatal Necrotizing Enterocolitis. Stem Cell Rev Rep. 2023;19(3):754–766. doi: https://doi.org/10.1007/s12015-022-10470-5
27. O’Connell JS, Lee C, Farhat N, et al. Administration of extracellular vesicles derived from human amniotic fluid stem cells: a new treatment for necrotizing enterocolitis. Pediatr Surg Int. 2021;37(3):301–309. doi: https://doi.org/10.1007/s00383-020-04826-6
28. Li B, Lee C, O’Connell JS, et al. Activation of Wnt signaling by amniotic fluid stem cell-derived extracellular vesicles attenuates intestinal injury in experimental necrotizing enterocolitis. Cell Death Dis. 2020;11(9):750. doi: https://doi.org/10.1038/s41419-020-02964-2
29. Sodhi CP, Ahmad R, Jia H, et al. The administration of amnion-derived multipotent cell secretome ST266 protects against necrotizing enterocolitis in mice and piglets. Am J Physiol Gastrointest Liver Physiol. 2022;323(3):G265–G282. doi: https://doi.org/10.1152/ajpgi.00364.2021
30. McCulloh CJ, Olson JK, Wang Y, et al. Treatment of experimental necrotizing enterocolitis with stem cell-derived exosomes. J Pediatr Surg. 2018;53(6):1215–1220. doi: https://doi.org/10.1016/j.jpedsurg.2018.02.086
31. Jain SK, Baggerman EW, Mohankumar K, et al. Amniotic fluid-borne hepatocyte growth factor protects rat pups against experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2014;306(5):G361–G369. doi: https://doi.org/10.1152/ajpgi.00272.2013
32. Dvorak B, Khailova L, Clark JA, et al. Comparison of epidermal growth factor and heparin-binding epidermal growth factor-like growth factor for prevention of experimental necrotizing enterocolitis. J Pediatr Gastroenterol Nutr. 2008;47(1):11–18. doi: https://doi.org/10.1097/MPG.0b013e3181788618
33. Zani A, Cananzi M, Fascetti-Leon F, et al. Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism. Gut. 2014;63(2):300–309. doi: https://doi.org/10.1136/gutjnl-2012-303735
34. Sullivan SE, Calhoun DA, Maheshwari A, et al. Tolerance of simulated amniotic fluid in premature neonates. Ann Pharmacother. 2002;36(10):1518–1524. doi: https://doi.org/10.1345/aph.1A439
35. Lima-Rogel V, Ojeda MA, Villegas C, et al. Tolerance of an enterally administered simulated amniotic fluid-like solution by neonates recovering from surgery for congenital bowel abnormalities. J Perinatol. 2004;24(5):295–298. doi: https://doi.org/10.1038/sj.jp.7211080
36. Calhoun DA, Christensen RD. Hematopoietic growth factors in neonatal medicine: the use of enterally administered hematopoietic growth factors in the neonatal intensive care unit. Clin Perinatol. 2004;31(1):169–182. doi: https://doi.org/10.1016/j.clp.2004.03.001
37. El-Farrash RA, Gad GI, Abdelkader HM, et al. Simulated amniotic fluid-like solution given enterally to neonates after obstructive bowel surgeries: A randomized controlled trial. Nutrition. 2019;66:187–191. doi: https://doi.org/10.1016/j.nut.2019.05.001
38. Hosseini M, Azampour H, Raeisi S, et al. The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants. Turk J Pediatr. 2019;61(3):392–398. doi: https://doi.org/10.24953/turkjped.2019.03.011
Review
For citations:
Gasanov K.E., Sorogina L.V., Parfenov-Mamykin M.S., Tsaturova A.A. Methods of Possible Application of Cell-Free Amniotic Fluid Analogues in the Practice of a Pediatrician. Pediatric pharmacology. 2025;22(1):72–78. (In Russ.) https://doi.org/10.15690/pf.v22i1.2859
Views:
289
Email this article 